The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 224 participants.
Also called NCT03614260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 224 participants
- Sponsor
- Registry
-
NCT03614260
-
- Main results
- Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Belgium, France, Germany, Ireland, Netherlands, Switzerland, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03614260. Randomized; double masking; primary purpose treatment. Start 2018-12-14 (actual); primary completion 2022-12-21 (actual). Results posted on 2026-09-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
- Acronym
- RADIANCE-II
- Condition
- Hypertension
- Condition
- Vascular Diseases
- Condition
- Cardiovascular Diseases
- Intervention (Device)
- Paradise Renal Denervation System
- Intervention (Procedure)
- Renal Angiogram
- Lead sponsor
- ReCor Medical, Inc.
Record details
- Record id
cardio:ct-nct03614260- Content hash
5efdd4fa1fc2e79a0487249d3ee0e925fc46f2c46d5f0343d58b68ed2a8cdc72